Trisomy 21 consistently activates the interferon response
暂无分享,去创建一个
Ahwan Pandey | J. Espinosa | M. Galbraith | A. Pandey | K. D. Sullivan | J. DeGregori | Hannah C. Lewis | A. Hill | L. Jackson | Joseph M Cabral | Keith P. Smith | L. Liggett | Eliana B Gomez | Joaquín M Espinosa | James DeGregori | Leisa P Jackson | Matthew D Galbraith | Kelly D Sullivan | Hannah C Lewis | Amanda A Hill | Keith P Smith | L Alexander Liggett | Kelly D. Sullivan | Leisa P Jackson | Joseph M Cabral
[1] Jørgen H Olsen,et al. Low risk of solid tumors in persons with Down syndrome , 2016, Genetics in Medicine.
[2] D. Steensma,et al. A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML) , 2016, Clinical Cancer Research.
[3] Jianping Wang,et al. A direct cross-talk between interferon-γ and sonic hedgehog signaling that leads to the proliferation of neuronal precursor cells , 2010, Brain, Behavior, and Immunity.
[4] G. Smyth,et al. Functional transcriptome analysis of the postnatal brain of the Ts1Cje mouse model for Down syndrome reveals global disruption of interferon-related molecular networks , 2014, BMC Genomics.
[5] B. Jallal,et al. Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus , 2010, Arthritis research & therapy.
[6] M. Figueroa,et al. Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes. , 2013, Blood.
[7] Claudia Angelini,et al. AnaLysis of Expression on human chromosome 21, ALE-HSA21: a pilot integrated web resource , 2014, Database J. Biol. Databases Curation.
[8] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..
[9] Sannah Zoffmann,et al. White-to-brown metabolic conversion of human adipocytes by JAK inhibition , 2014, Nature Cell Biology.
[10] A. Tefferi,et al. Long-term outcome of treatment with ruxolitinib in myelofibrosis. , 2011, The New England journal of medicine.
[11] C. Schindler,et al. The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction. , 1993, Nature.
[12] S. Catuara-Solarz,et al. A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials , 2015, Front. Psychol..
[13] Dean Nizetic,et al. A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome , 2015, Nature Reviews Neuroscience.
[14] C. Epstein,et al. Human Chromosome 21 Dosage: Effect on the Expression of the Interferon Induced Antiviral State , 1974, Science.
[15] P. Cheah,et al. Potential Role of JAK-STAT Signaling Pathway in the Neurogenic-to-Gliogenic Shift in Down Syndrome Brain , 2016, Neural plasticity.
[16] H. Kantarjian,et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. , 2010, Blood.
[17] M. L. Montesinos,et al. The Akt-mTOR pathway in Down's syndrome: the potential use of rapamycin/rapalogs for treating cognitive deficits. , 2014, CNS & neurological disorders drug targets.
[18] J. Lawrence,et al. Presence of human chromosome 21 alone is sufficient for hybrid cell sensitivity to human interferon , 1978, Journal of virology.
[19] J. Treuner,et al. Interferon alpha-2a therapy in haemangiomas of infancy: spastic diplegia as a severe complication , 1999, European Journal of Pediatrics.
[20] D. Spaner,et al. Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial , 2016, Haematologica.
[21] Borut Peterlin,et al. Expression Signature as a Biomarker for Prenatal Diagnosis of Trisomy 21 , 2013, PloS one.
[22] Stephen A. Williams,et al. Validation of a blood protein signature for non-small cell lung cancer , 2014, Clinical Proteomics.
[23] S. Izraeli,et al. Haematopoietic development and leukaemia in Down syndrome , 2014, British journal of haematology.
[24] T. Johnson,et al. INHIBITION OF PROTEIN SYNTHESIS IN NONINFECTED L CELLS BY PARTIALLY PURIFIED INTERFERON PREPARATIONS , 1968, The Journal of cell biology.
[25] J. Crispino,et al. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome. , 2012, The Journal of clinical investigation.
[26] M. Genovese,et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate , 2014, Annals of the rheumatic diseases.
[27] Henry W. Long,et al. HIF1A Employs CDK8-Mediator to Stimulate RNAPII Elongation in Response to Hypoxia , 2013, Cell.
[28] M. Wichers,et al. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. , 2004, Journal of psychiatry & neuroscience : JPN.
[29] G. Yancopoulos,et al. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. , 1994, Science.
[30] L. Maroun. Anti-interferon immunoglobulins can improve the trisomy 16 mouse phenotype. , 1995, Teratology.
[31] D. Felsher,et al. MYC as a regulator of ribosome biogenesis and protein synthesis , 2010, Nature Reviews Cancer.
[32] P. Brown,et al. Dissecting Interferon-Induced Transcriptional Programs in Human Peripheral Blood Cells , 2010, PloS one.
[33] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[34] Pei Wang,et al. Effects of small interfering RNAs targeting MAPK1 on gene expression profile in HeLa cells as revealed by microarray analysis , 2008, Cell biology international.
[35] Alan G Hinnebusch,et al. The scanning mechanism of eukaryotic translation initiation. , 2014, Annual review of biochemistry.
[36] L. Zitvogel,et al. Type I interferons in anticancer immunity , 2015, Nature Reviews Immunology.
[37] N. Nowak,et al. Duplication of the entire 22.9 Mb human chromosome 21 syntenic region on mouse chromosome 16 causes cardiovascular and gastrointestinal abnormalities. , 2007, Human molecular genetics.
[38] J. Dambrosia,et al. Interferons and cerebral palsy. , 1999, The Journal of pediatrics.
[39] Sarah L McGlasson,et al. Type I interferon dysregulation and neurological disease , 2015, Nature Reviews Neurology.
[40] M. Maes,et al. IDO and interferon-α-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity , 2005, Molecular Psychiatry.
[41] Christopher C. Porter,et al. ATM and MET kinases are synthetic lethal with non-genotoxic activation of p53 , 2012, Nature chemical biology.
[42] H. Drexler,et al. Detection of mycoplasma in leukemia–lymphoma cell lines using polymerase chain reaction , 2002, Leukemia.
[43] Cole Trapnell,et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions , 2013, Genome Biology.
[44] D. Linden,et al. Hedgehog Agonist Therapy Corrects Structural and Cognitive Deficits in a Down Syndrome Mouse Model , 2013, Science Translational Medicine.
[45] D. Walsh,et al. Tinkering with translation: protein synthesis in virus-infected cells. , 2013, Cold Spring Harbor perspectives in biology.
[46] D. Butterfield,et al. mTOR signaling in aging and neurodegeneration: At the crossroad between metabolism dysfunction and impairment of autophagy , 2015, Neurobiology of Disease.
[47] R. Carlson,et al. Solid malignancies in individuals with Down syndrome: a case presentation and literature review. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.
[48] J. Mulliken,et al. Spastic Diplegia as a Complication of Interferon Alfa‐2a Treatment of Hemangiomas of Infancy , 1998, The Journal of pediatrics.
[49] G. Plosker. Ruxolitinib: A Review of Its Use in Patients with Myelofibrosis , 2015, Drugs.
[50] A. Christiano,et al. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib , 2015, EBioMedicine.
[51] Takashi Nakamura,et al. Influences of interferon-gamma on cell proliferation and interleukin-6 production in Down syndrome derived fibroblasts. , 2009, Archives of oral biology.
[52] Matthew J. Stephens,et al. Changes in Gene Expression during Pegylated Interferon and Ribavirin Therapy of Chronic Hepatitis C Virus Distinguish Responders from Nonresponders to Antiviral Therapy , 2007, Journal of Virology.
[53] C. Dang,et al. Induction of ribosomal genes and hepatocyte hypertrophy by adenovirus-mediated expression of c-Myc in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[54] A. Dhanasekaran,et al. Protein profiles in Tc1 mice implicate novel pathway perturbations in the Down syndrome brain , 2013, Human molecular genetics.
[55] M Schwab,et al. N‐myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis , 2001, The EMBO journal.
[56] Paul Theodor Pyl,et al. HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.
[57] W. Mobley,et al. Questioned validity of Gene Expression Dysregulated Domains in Down's Syndrome , 2015, F1000Research.
[58] M. V. Capela,et al. Expression of interferon-γ, interferon-α and related genes in individuals with Down syndrome and periodontitis. , 2012, Cytokine.
[59] Christopher C. Ebmeier,et al. CDK8 is a positive regulator of transcriptional elongation within the serum response network , 2010, Nature Structural &Molecular Biology.
[60] Bing Zhang,et al. WebGestalt: an integrated system for exploring gene sets in various biological contexts , 2005, Nucleic Acids Res..
[61] K. McKeage. Ruxolitinib: A Review in Polycythaemia Vera , 2015, Drugs.
[62] L. Maroun. Interferon-mediated effect on ribosomal RNA metabolism. , 1978, Biochimica et biophysica acta.
[63] Gary D. Bader,et al. Pathway Commons, a web resource for biological pathway data , 2010, Nucleic Acids Res..
[64] A. Ciccodicola,et al. Massive-Scale RNA-Seq Analysis of Non Ribosomal Transcriptome in Human Trisomy 21 , 2011, PloS one.
[65] Stylianos E. Antonarakis,et al. Domains of genome-wide gene expression dysregulation in Down’s syndrome , 2014, Nature.
[66] Lars-Gunnar Larsson,et al. c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription , 2005, Nature Cell Biology.
[67] Y. Crow,et al. Aicardi–Goutières syndrome and the type I interferonopathies , 2015, Nature Reviews Immunology.
[68] N. Morgan,et al. Immunopathology of the human pancreas in type-I diabetes , 2011, Seminars in Immunopathology.
[69] Jing Wang,et al. WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013 , 2013, Nucleic Acids Res..
[70] Hyungwon Choi,et al. QPROT: Statistical method for testing differential expression using protein-level intensity data in label-free quantitative proteomics. , 2015, Journal of proteomics.
[71] B. Teh,et al. Molecular characterization of human telomerase reverse transcriptase-immortalized human fibroblasts by gene expression profiling: activation of the epiregulin gene. , 2003, Cancer research.
[72] V. Srikanth,et al. Risk of Major Cardiovascular Events in People with Down Syndrome , 2015, PloS one.
[73] G. Stark,et al. The protein tyrosine kinase JAK1 complements defects in interferon-α/β and -γ signal transduction , 1993, Nature.
[74] Wei Li,et al. RSeQC: quality control of RNA-seq experiments , 2012, Bioinform..
[75] J. Darnell,et al. Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions , 1994, Cell.
[76] Charles M. Rice,et al. Corrigendum: A diverse range of gene products are effectors of the type I interferon antiviral response , 2015, Nature.
[77] J. Crispino,et al. AKT collaborates with ERG and Gata1s to dysregulate megakaryopoiesis and promote AMKL , 2013, Leukemia.
[78] Milton W. Taylor,et al. Suppression of ribosomal protein synthesis and protein translation factors by Peg-interferon alpha/ribavirin in HCV patients blood mononuclear cells (PBMC) , 2012, Journal of Translational Medicine.
[79] Larry Gold,et al. Advances in human proteomics at high scale with the SOMAscan proteomics platform. , 2012, New biotechnology.
[80] P. Chambon,et al. Tripartite Motif 24 (Trim24/Tif1α) Tumor Suppressor Protein Is a Novel Negative Regulator of Interferon (IFN)/Signal Transducers and Activators of Transcription (STAT) Signaling Pathway Acting through Retinoic Acid Receptor α (Rarα) Inhibition* , 2011, The Journal of Biological Chemistry.
[81] B. Frier,et al. Type 1 diabetes mellitus and Down's syndrome: prevalence, management and diabetic complications , 1998, Diabetic medicine : a journal of the British Diabetic Association.
[82] P. Scherle,et al. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers , 2014, Journal of clinical pharmacology.
[83] Eric P. Hoffman,et al. Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy , 2015, Proceedings of the National Academy of Sciences.
[84] Andreas Krämer,et al. Causal analysis approaches in Ingenuity Pathway Analysis , 2013, Bioinform..
[85] H. Petri,et al. Morbidity and medication in a large population of individuals with Down syndrome compared to the general population , 2016, Developmental medicine and child neurology.
[86] E. Aronica,et al. mTOR Hyperactivation in down syndrome hippocampus appears early during development. , 2014, Journal of neuropathology and experimental neurology.
[87] T. Heffernan,et al. Partial IFN-alpha/beta and IFN-gamma receptor knockout trisomy 16 mouse fetuses show improved growth and cultured neuron viability. , 2000, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.